Nanomedicine - European Science Foundation

5
Contents
Foreword 6
Executive Summary 7
1. Nanomedicine: A New Opportunity for Improved Diagnosis, Prevention and Treatment for Disease 11
1.1. Definition of Nanomedicine 11
1.2. Position of Nanomedicines within the Healthcare Portfolio 11
2. Current Status of Nanomedicine Research and Forward Look 13
2.1. Science and Technology 13
2.1.1. Workshop on Analytical Techniques and Diagnostic Tools
2.1.2. Workshop on Nanoimaging and Manipulation
2.1.3. Workshop on Nanomaterials and Nanodevices
2.1.4. Workshop on Drug Delivery and Pharmaceutical Development
2.1.5. Workshop on Clinical Use, Regulatory and Toxicology Issues
2.2. Research Strategy and Policy 21
2.2.1. Organisation and Funding
2.2.2. Commercial Exploitation
2.2.3. Interdisciplinary Education and Training
2.2.4. Communication
3. European Situation and Forward Look – SWOT Analysis 25
4. Recommendations and Suggested Actions 29
4.1. General Recommendations 29
4.1.1. Priority Areas in Nanomedicine for the next 5 years
4.1.2. Priority Areas in Nanomedicine for the next 10 years
4.1.3. Commercial Exploitation
4.1.4. Interdisciplinary Education and Training
4.2. Scientific Trends 29
4.2.1. Nanomaterials and Nanodevices
4.2.2. Nanoimaging and Analytical Tools
4.2.3. Novel Therapeutics and Drug Delivery Systems
4.2.4. Clinical Applications and Regulatory Issues
4.2.5. Toxicology
4.3. Research Strategy and Policy 30
4.3.1. Organisation and Funding
4.3.2. Commercial Exploitation
4.3.3. Interdisciplinary Education and Training
4.3.4. Communication
5. Bibliography 32
5.1. Key Reports on Nanotechnology and Nanomedicine 32
5.2. Key Literature on Nanotechnology relating to Medicine 33
5.3. Websites and General Information 35
6. Appendices 37
Appendix I. ESF Forward Look Workshop Participants 37
Appendix II. ESF Forward Look Consensus Conference Participants 39
Appendix III. Projected Market for Nanomedicines 43
Appendix IV. European Projects and Networks Undertaking Nanomedicine Research 43
Appendix V. Nanomedicines in Routine Clinical Use or Clinical Development 45
Appendix VI. European Companies Active in Nanomedicines’ Development 47